25 April 2018 - - Dublin, Ireland-based biopharmaceutical company Theravance Biopharma, Inc. (NASDAQ: TBPH) has presented positive new data from multiple studies of Vibativ (telavancin) at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), the company said.
Two presentations were made reporting new data from the Telavancin Observational Use Registry (TOUR) study, which is designed to report how Vibativ (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings.
The presented findings, which focus on data from registry patients classified as elderly or obese, report positive clinical responses for Vibativ treatment ranging from 76.5% to 78.8% in these patient subgroups. Positive clinical response was defined as cure or improvement leading to step-down oral therapy.
Vibativ is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours, and penetration into target infection sites.
The drug is approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.
In addition, Vibativ is approved in the US for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including S. aureus, both methicillin-susceptible and methicillin-resistant strains.
The product labeling also describes the use of Vibativ in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia.
Theravance Biopharma's pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions, primarily in the acute care setting.
The company's research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and intestinal tract in order to maximize patient benefit and minimize risk.